Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,185,100.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $545.80, for a total transaction of $5,185,100.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,111,995.40. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $555.91 on Friday. The business has a fifty day simple moving average of $558.71 and a two-hundred day simple moving average of $527.64. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The company has a market capitalization of $23.60 billion, a price-to-earnings ratio of 20.52, a P/E/G ratio of 1.80 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.63 EPS. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of a number of analyst reports. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America lifted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Royal Bank Of Canada cut their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $619.42.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the business. Torren Management LLC bought a new stake in United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.